CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

In a report released yesterday, Lance Wilkes from Bernstein maintained a Hold rating on CVS Health, with a price target of $72.00. The company’s shares closed yesterday at $63.80. Wilkes covers the ...

Detailed price information for Unitedhealth Group Inc (UNH-N) from The Globe and Mail including charting and trades.

CVS Health has secured a major healthcare deal, winning a multi-year pharmacy benefits contract with CalPERS, outbidding rival UnitedHealth. The deal marks a significant win for CVS's Caremark unit ...

Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

Renault slashed its financial targets for the year, citing a worsening automotive market as the group faces stiff competition from rivals, and elevated finance chief Duncan Minto to interim CEO. J.B.

CVS Health’s Caremark business signed a new pharmacy benefits contract with the California Public Employees’ Retirement System, known as Calpers.